APA (7th ed.) Citation

Chevallier, P., Hunault-Berger, M., Larosa, F., Dauriac, C., Garand, R., & Harousseau, J. (2009). A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial. Leukemia Research, 33(8), 1124. https://doi.org/10.1016/j.leukres.2008.09.030

Chicago Style (17th ed.) Citation

Chevallier, Patrice, Mathilde Hunault-Berger, Fabrice Larosa, Charles Dauriac, Richard Garand, and Jean-Luc Harousseau. "A Phase II Trial of High-dose Imatinib Mesylate for Relapsed or Refractory C-kit Positive and Bcr-Abl Negative Acute Myeloid Leukaemia: The AFR-15 Trial." Leukemia Research 33, no. 8 (2009): 1124. https://doi.org/10.1016/j.leukres.2008.09.030.

MLA (9th ed.) Citation

Chevallier, Patrice, et al. "A Phase II Trial of High-dose Imatinib Mesylate for Relapsed or Refractory C-kit Positive and Bcr-Abl Negative Acute Myeloid Leukaemia: The AFR-15 Trial." Leukemia Research, vol. 33, no. 8, 2009, p. 1124, https://doi.org/10.1016/j.leukres.2008.09.030.